Sildenafil works by blocking an enzyme called phosphodiesterase type 5, usually shortened to PDE5. PDE5 normally helps break down a signaling molecule called cGMP, so inhibiting the enzyme changes how quickly that signal is removed after it has been produced.
When sildenafil inhibits PDE5, cGMP is broken down more slowly. That allows an existing biological signal to persist differently than it would without PDE5 inhibition, but it does not mean sildenafil creates the original signal or directly manufactures cGMP.
The important point is that sildenafil supports an existing signaling pathway rather than switching it on from nothing. This page explains that sequence in plain language and focuses on the core mechanism, while more technical questions about enzyme pharmacology, concentration-effect relationships and PK/PD interpretation remain on the site's dedicated research pages.
The easiest way to understand sildenafil is as a regulator of an existing signaling pathway. It does not create the whole biological response by itself; instead, it changes one step in a sequence that is already being activated upstream.
First, the body produces an upstream signal. That signal leads to formation of cGMP, a molecule that carries information inside cells and participates in downstream physiological responses.
PDE5 normally breaks cGMP down and therefore helps limit how long that signaling persists. Sildenafil reduces PDE5-mediated breakdown, allowing cGMP to remain available longer than it otherwise would while the pathway is active.
| Step | What Happens |
|---|---|
| 1 | An upstream biological signal begins. |
| 2 | cGMP is produced. |
| 3 | PDE5 breaks cGMP down. |
| 4 | Sildenafil inhibits PDE5. |
| 5 | cGMP is broken down more slowly. |
PDE5 is an enzyme. Enzymes are proteins that help control chemical processes in the body, and phosphodiesterase enzymes are involved in regulating signaling molecules after those molecules have carried out part of their function.
One of PDE5's roles is to break down cGMP, which helps limit how long certain signals remain active. In that sense, PDE5 acts as part of the pathway's built-in regulation rather than as the source of the original signal.
Sildenafil is called a PDE5 inhibitor because it reduces the activity of this enzyme. The important plain-language idea is that inhibiting PDE5 changes cGMP breakdown; the more detailed target-level pharmacology is covered separately elsewhere in the research section.
| Term | Plain-English Meaning |
|---|---|
| PDE5 | An enzyme involved in breaking down cGMP. |
| Inhibitor | Something that reduces an enzyme's activity. |
| Sildenafil | A medicine that inhibits PDE5. |
cGMP is a signaling molecule used by cells to pass along biological information. It is part of a broader intracellular signaling system, meaning its role is best understood as one step in a sequence rather than as an isolated substance acting on its own.
Its level depends on a balance between how much is produced and how quickly it is broken down. Upstream signaling promotes its formation, while enzymes such as PDE5 contribute to its removal and help regulate the persistence of the signal.
Sildenafil does not directly make cGMP. Instead, it affects the breakdown side of that balance by inhibiting PDE5, which changes how long already-produced cGMP can remain available within the pathway.
| cGMP Concept | Meaning |
|---|---|
| Production | Created through upstream signaling. |
| Function | Carries signals inside cells. |
| Breakdown | Controlled partly by PDE5. |
Nitric oxide, often abbreviated NO, is part of the upstream signaling process that leads to cGMP production. It belongs earlier in the sequence than PDE5 inhibition and helps explain why sildenafil is described as supporting an existing pathway rather than independently creating the entire response.
Sildenafil does not directly create nitric oxide and does not replace the upstream signal. Its action occurs later in the pathway, after signaling has already led to production of cGMP.
This is why the drug is better understood as modifying an active pathway rather than generating the entire response on its own. Separating the upstream signal from PDE5-mediated cGMP breakdown is one of the most useful ways to understand the mechanism without oversimplifying it.
| Component | Role |
|---|---|
| Nitric oxide | Helps start the upstream signaling sequence. |
| cGMP | Carries the intracellular signal. |
| PDE5 | Breaks cGMP down. |
| Sildenafil | Reduces PDE5-mediated breakdown. |
Sildenafil's main mechanistic role is to inhibit PDE5. That target interaction is the central pharmacological action behind its classification as a PDE5 inhibitor and is the starting point for understanding the rest of the mechanism.
By doing so, it slows one of the processes that removes cGMP from the signaling pathway. This shifts the balance away from rapid breakdown while the upstream pathway is active, allowing cGMP-dependent signaling to persist differently than it would without PDE5 inhibition.
The result is not a new signal, but a change in how an existing signal is maintained. This distinction matters because it prevents the mechanism from being described as though sildenafil independently creates nitric oxide, directly produces cGMP or switches on the entire biological response.
| Statement | Correct? |
|---|---|
| Sildenafil inhibits PDE5 | Yes |
| Sildenafil directly creates nitric oxide | No |
| Sildenafil directly manufactures cGMP | No |
| Sildenafil changes cGMP breakdown | Yes |
Understanding the mechanism does not mean sildenafil produces the same response in every person. Knowing the molecular target explains an important part of how the drug can act, but it does not describe every biological or clinical factor that influences an observed response.
A drug's molecular target is only one part of what determines an observed effect. Absorption, metabolism, changing drug concentrations, signaling activity and individual biology also matter, so the same basic mechanism can exist alongside meaningful variability in timing or response.
Mechanism therefore explains how the medicine can act, not exactly what every individual will experience. It should be treated as a foundation for understanding the drug rather than as a guarantee of a particular onset, duration or outcome.
| Mechanism Can Explain | Mechanism Cannot Guarantee |
|---|---|
| Which enzyme sildenafil targets | A specific personal response |
| How cGMP breakdown is affected | Exact onset timing |
| Why sildenafil is a PDE5 inhibitor | Exact effect duration |
Not by itself. Sildenafil must first be absorbed and reach relevant concentrations before PDE5 inhibition can contribute to an observable effect, so a description of the molecular target cannot on its own establish when that effect will become noticeable.
That means onset depends on pharmacokinetics as well as mechanism. Absorption, changing plasma concentration, target interaction and downstream signaling occur in sequence, and these processes should not be collapsed into a single timing measurement.
The timing concept is explained separately on the sildenafil onset page, where onset is kept distinct from peak plasma concentration. That separation allows this page to stay focused on mechanism without turning a mechanistic explanation into a timing guide.
| Timing Step | Role |
|---|---|
| Absorption | Makes sildenafil systemically available. |
| Target interaction | Allows PDE5 inhibition. |
| Downstream signaling | Translates target interaction into biological response. |
| Observed onset | When an effect becomes noticeable or measurable. |
The mechanism helps explain why sildenafil can have an effect, but it does not by itself define the full duration of that effect. PDE5 inhibition describes what the drug does at its target, whereas duration describes how long an observable response persists within a changing biological and pharmacokinetic context.
Duration depends on changing drug concentrations, continued target interaction and the behavior of the signaling pathway over time. As sildenafil concentrations rise and fall, the degree of target engagement can also change, which is one reason mechanism and duration should be treated as related but separate concepts.
The difference between effect duration and plasma half-life is covered on the sildenafil duration page. Keeping those concepts separate avoids the common mistake of treating a pharmacokinetic measurement as though it directly defines the entire period of clinical effect.
| Concept | What It Describes |
|---|---|
| Mechanism | How sildenafil acts at its target. |
| Half-life | How plasma concentration declines. |
| Duration | How long an observed effect persists. |
The basic molecular mechanism does not change simply because exposure changes. Sildenafil still acts by inhibiting PDE5, so increasing or decreasing the amount of drug does not create a different fundamental target or a different core mechanism.
Higher or lower exposure can affect the degree and timing of target interaction, but the relationship between exposure and response is not a simple one-to-one rule. Drug concentration, receptor or enzyme interaction, downstream signaling and individual biological variability all contribute to the observed result.
Dose and exposure questions belong to pharmacokinetic and prescribing contexts rather than to a plain-language mechanism explanation. This page therefore keeps the focus on what sildenafil does at the molecular target rather than turning exposure differences into dosage guidance.
| Concept | Interpretation |
|---|---|
| Mechanism | PDE5 inhibition remains the core action. |
| Exposure | Can change how much drug is available. |
| Response | Depends on more than exposure alone. |
The core molecular mechanism comes from sildenafil itself rather than from the brand name. When sildenafil is the active ingredient, its fundamental target remains PDE5 and the basic pharmacological mechanism continues to involve reduced PDE5-mediated breakdown of cGMP.
That means sildenafil-containing products such as Viagra and Revatio share the same basic PDE5-inhibitor pharmacology even though their approved indications and product contexts differ. Brand identity, formulation, labeling and clinical use context should therefore be separated from the underlying active-ingredient mechanism.
The differences between those brands are explained separately on the Viagra vs Revatio page. Keeping product context separate from mechanism helps avoid the mistaken idea that a different brand name necessarily means a different molecular action.
| Level | What Can Differ? |
|---|---|
| Active ingredient | Sildenafil remains sildenafil. |
| Core mechanism | PDE5 inhibition remains the same. |
| Brand | Can differ. |
| Approved use | Can differ. |
Sildenafil is not the only PDE5 inhibitor. Tadalafil, vardenafil and avanafil also act on the same broad enzyme target, which is why these medicines are grouped within the same pharmacological class.
Sharing a mechanism class does not make these medicines identical because their pharmacokinetic and product characteristics differ. Members of the same drug class can vary in absorption patterns, elimination profiles, formulation, labeled use and other properties even when they share a central target.
A high-level comparison is available on the sildenafil vs other PDE5 inhibitors page. That page addresses class-level differences while this section simply explains why sildenafil belongs to the PDE5 inhibitor family.
| Medicine | Shared Class Feature |
|---|---|
| Sildenafil | PDE5 inhibitor |
| Tadalafil | PDE5 inhibitor |
| Vardenafil | PDE5 inhibitor |
| Avanafil | PDE5 inhibitor |
Mechanism explains what sildenafil does once it reaches its biological target. Pharmacokinetics explains how the drug gets into the body, reaches systemic circulation, distributes, is metabolized and eliminated, and how its concentration changes over time.
Those are different questions even though they interact in practice. A medicine can have a well-understood molecular mechanism while its concentration profile varies between people or circumstances, which means target action and drug disposition should not be treated as interchangeable concepts.
The technical ADME side is covered on the sildenafil pharmacokinetics page. Separating mechanism from PK allows this page to remain a plain-language guide while the research hub handles absorption, exposure, metabolism, clearance and related measurements in greater depth.
| Question | Topic |
|---|---|
| What enzyme does sildenafil inhibit? | Mechanism |
| How is sildenafil absorbed? | Pharmacokinetics |
| When does concentration peak? | Pharmacokinetics |
| How does target interaction lead to response? | Pharmacodynamics |
At a plain-language level, the mechanism can be summarized as sildenafil slowing the breakdown of cGMP by inhibiting PDE5. That explanation captures the essential sequence without requiring a detailed discussion of enzyme kinetics, selectivity or concentration-response modeling.
Technical pharmacology goes further by examining enzyme selectivity, concentration-effect relationships, signaling steps and downstream response. Those questions require more precise terminology and often depend on experimental or clinical pharmacology data rather than a simple overview of the pathway.
Those deeper topics are intentionally separated into sildenafil pharmacodynamics, PDE5 inhibition and the NO-cGMP pathway research pages. This division keeps the current page accessible while still giving readers a route into the more technical evidence.
| Page Type | Focus |
|---|---|
| How sildenafil works | Plain-language mechanism. |
| Pharmacodynamics | Technical drug-response framework. |
| PDE5 inhibition | Target-specific molecular detail. |
| NO-cGMP pathway | Detailed signaling sequence. |
Sildenafil works by inhibiting PDE5, an enzyme that normally breaks down cGMP. Inhibiting that enzyme changes one regulatory step within an already active signaling pathway rather than creating the entire pathway from the beginning.
By slowing that breakdown, sildenafil allows cGMP signaling to persist differently within an already active biological pathway. The drug therefore modifies how an existing signal is maintained rather than directly producing nitric oxide or manufacturing cGMP itself.
The mechanism explains the drug's core action, but timing, duration and individual response require additional pharmacokinetic and pharmacodynamic context. Understanding that boundary is important because mechanism describes what sildenafil does at its target, not every factor that determines what a person ultimately experiences.
| Question | Plain-English Answer |
|---|---|
| What does sildenafil block? | PDE5. |
| What does PDE5 normally do? | Helps break down cGMP. |
| Does sildenafil make nitric oxide? | No. |
| Does it create cGMP directly? | No. |
| What does it change? | How quickly cGMP is broken down. |
Sildenafil inhibits PDE5, an enzyme that breaks down cGMP. This slows cGMP breakdown and changes how long signaling can persist within an already active biological pathway.
PDE5 is an enzyme involved in breaking down cGMP, a signaling molecule used in several biological processes. By regulating cGMP breakdown, PDE5 helps control how long certain signals remain active.
No. Sildenafil does not directly create nitric oxide. Nitric oxide acts earlier in the signaling sequence, while sildenafil acts later by inhibiting PDE5.
No. Sildenafil does not directly produce cGMP. It reduces the rate at which PDE5 breaks down cGMP that has already been produced through upstream signaling.
Not completely. Onset also depends on absorption, changing drug concentration, target interaction and downstream biological response, so mechanism alone does not define exact timing.
Yes. Their core molecular action comes from sildenafil and therefore involves PDE5 inhibition, although the products have different approved-use and labeling contexts.